New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 305.85mg equivalent to valaciclovir base 250 mg - film coated tablet - 250 mg - active: valaciclovir hydrochloride monohydrate 305.85mg equivalent to valaciclovir base 250 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg - film coated tablet - 500 mg - active: valaciclovir hydrochloride monohydrate 611.7mg equivalent to valaciclovir base 500 mg excipient: magnesium stearate microcrystalline cellulose opadry white y-5-7068 povidone - valaciclovir actavis is indicated for the treatment of herpes zoster (shingles) and the reduction of zoster - associated pain, which includes acute and post herpetic neuralgia, when given to immunocompetent patients in infection of less than 72 hours duration.

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - valaciclovir hydrochloride monohydrate - film coated tablet - 500 milligram - nucleosides and nucleotides excl. reverse transcriptase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - valaciclovir hydrochloride monohydrate - film coated tablet - 500 milligram - valaciclovir

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 556 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: povidone; crospovidone; colloidal anhydrous silica; carnauba wax; magnesium stearate; microcrystalline cellulose; colour - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores) for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valtrex, it is recommended that patients use safer sex practices. (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - valaciclovir hydrochloride, quantity: 1112.48 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 400; maize starch; povidone; magnesium stearate; hypromellose; croscarmellose sodium; polysorbate 80; lactose monohydrate - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of recurrent herpes labialis (cold sores); treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - valaciclovir hydrochloride, quantity: 556.24 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: hypromellose; povidone; polysorbate 80; titanium dioxide; maize starch; magnesium stearate; macrogol 400; lactose monohydrate; croscarmellose sodium - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of recurrent herpes labialis (cold sores); treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - valaciclovir hydrochloride monohydrate, quantity: 1223.4 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of opthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with altic, it is recommended that patients use safer sex practices (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - valaciclovir hydrochloride, quantity: 1112.48 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 400; maize starch; povidone; magnesium stearate; hypromellose; croscarmellose sodium; polysorbate 80; lactose monohydrate - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of recurrent herpes labialis (cold sores); treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - valaciclovir hydrochloride, quantity: 1112.48 mg (equivalent: valaciclovir, qty 1000 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; povidone; croscarmellose sodium; titanium dioxide; magnesium stearate; hypromellose; macrogol 400; polysorbate 80 - treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash; treatment of ophthalmic zoster; treatment of recurrent herpes labialis (cold sores); treatment of clinical episodes of genital herpes simplex infections; prevention of recurrent genital herpes; reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions); prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.